Multitarget therapeutic strategies for Alzheimer's disease

• Published in: Neural regeneration research Vol. 14; no. 3; pp. 437 - 440
• Main Authors: Ibrahim, Mostafa, Gabr, Moustafa
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.03.2019; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Department of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA%Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; Department of Chemistry, University of Iowa, Iowa City, IA, USA; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Alzheimer's disease; Animal cognition; Blood-brain barrier; Brain; Criminal investigation; Dementia; Development and progression; Disease; Drugs; Enzymes; FDA approval; Genetic aspects; Hybridization; Kinases; Ligands; Memory; Metabolism; multitarget-directed ligands; acetylcholinesterase; β-secretase; Alzheimer′s disease; hybridization; neurodegenerative diseases; tacrine; brain permeability; Neurodegeneration; Neurodegenerative diseases; Neurological disorders; Neurotoxicity; Oxidative stress; Pathogenesis; Peptides; Permeability; Proteins; Review; neurodegenerative diseases; multitarget-directed ligands; tacrine; β-secretase; acetylcholinesterase; hybridization; Alzheimer's disease; brain permeability
• ISSN: 1673-5374; 1876-7958
• DOI: 10.4103/1673-5374.245463

Neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neurodegenerative diseases has developed a pressing need to design multitarget-directed ligands to address the complementary pathways involved in these diseases. The major enzyme targets for development of therapeutics for Alzheimer's disease are cholinesterase and β-secretase enzymes. In this review, we discuss recent advances in profiling single target inhibitors based on these enzymes to multitarget-directed ligands as potential therapeutics for this devastating disease. In addition, therapeutics based on iron chelation strategy are discussed as well.